Literature DB >> 8733975

The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.

F G Moser1, S T Miller, J A Bello, C H Pegelow, R A Zimmerman, W C Wang, K Ohene-Frempong, A Schwartz, E P Vichinsky, D Gallagher, T R Kinney.   

Abstract

PURPOSE: To define the spectrum of abnormalities in sickle-cell disease, including infarction, atrophy, and hemorrhage, that are identified by brain MR imaging.
METHODS: All MR studies included T1, T2, and intermediate pulse sequences. Images were interpreted without knowledge of the clinical history or neurologic examination findings. Brain MR imaging was performed in 312 children with sickle-cell disease.
RESULTS: Seventy patients (22%) had infarction/ischemia and/or atrophy, infarction/ischemia was noted in 39 children (13%) who had no history of a stroke (the "silent" group). The prevalence rates for silent lesions were 17% for sickle-cell anemia and 3% for hemoglobin sickle-cell disease. For patients with sickle-cell anemia and a history of cerebrovascular accident, infarction/ischemia lesions typically involved both cortex and deep white matter, while silent lesions usually were confined to deep white matter. Within the age range studied, the prevalence of infarction/ischemia did not increase significantly with age, although older patients with lesions had more lesions than did younger patients with lesions.
CONCLUSIONS: Brain MR imaging showed infarction/ischemia in the absence of a recognized cerebrovascular accident in 13% of patients. The prevalence of these lesions did not increase significantly between the ages of 6 and 14 years, suggesting that lesions are present by age 6. However, the increase in the average number of lesions per patient with age may indicate progressive brain injury.

Entities:  

Mesh:

Year:  1996        PMID: 8733975      PMCID: PMC8337529     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  53 in total

1.  Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II.

Authors:  Miguel R Abboud; Eunsil Yim; Khaled M Musallam; Robert J Adams
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

Review 2.  Managing sickle cell disease.

Authors:  Susan Claster; Elliott P Vichinsky
Journal:  BMJ       Date:  2003-11-15

Review 3.  Imaging in childhood arterial ischaemic stroke.

Authors:  Brynmor P Jones; Vijya Ganesan; Dawn E Saunders; W Kling Chong
Journal:  Neuroradiology       Date:  2010-05-06       Impact factor: 2.804

4.  MRI/MRA evaluation of sickle cell disease of the brain.

Authors:  Robert A Zimmerman
Journal:  Pediatr Radiol       Date:  2005-02-10

5.  Sickle cell vasculopathy mini-symposium: editor's overview.

Authors:  Dorothy Bulas
Journal:  Pediatr Radiol       Date:  2005-02-10

Review 6.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

7.  Large-Vessel Vasculopathy in Children With Sickle Cell Disease: A Magnetic Resonance Imaging Study of Infarct Topography and Focal Atrophy.

Authors:  Kristin P Guilliams; Melanie E Fields; Dustin K Ragan; Yasheng Chen; Cihat Eldeniz; Monica L Hulbert; Michael M Binkley; James N Rhodes; Joshua S Shimony; Robert C McKinstry; Katie D Vo; Hongyu An; Jin-Moo Lee; Andria L Ford
Journal:  Pediatr Neurol       Date:  2016-12-07       Impact factor: 3.372

Review 8.  Ischemic strokes in children.

Authors:  L E Walsh; B P Garg
Journal:  Indian J Pediatr       Date:  1997 Sep-Oct       Impact factor: 1.967

Review 9.  Neuroimaging findings in sickle cell disease.

Authors:  S C Thust; C Burke; A Siddiqui
Journal:  Br J Radiol       Date:  2014-05-21       Impact factor: 3.039

10.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.